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Chronic inflammatory demyelinating polyneuropathy as a paraneoplastic manifestation of
colorectal carcinoma: What do we know?
The pathogenesis of chronic inflammatory demyelinating poly
neuropathy (CIDP) remains highly debated among experts. In recent
times, literature has divulged a riveting yet plausible association be
tween colorectal carcinoma and CIDP as its paraneoplastic ramification.
Initially, research suggested that chronic inflammatory demyelinating
polyneuropathy (CIDP) was caused solely by macrophages [1]. How
ever, recent studies have insinuated towards an alternative pathogen
esis, one involving autoantibodies against paranodal junction proteins
[2]. These two distinct mechanisms are the primary contenders
responsible for the development of CIDP, rendering it an elusive para
neoplastic manifestation of colorectal carcinoma.
Traditionally, macrophages have been purported to be responsible
for the phagocytosis of the myelin surrounding peripheral neurons [1].
A recent study divulged that macrophage-induced demyelination is not
only responsible for classical CIDP but also atypical CIDP such as distal
acquired disseminated symmetric (DADS) CIDP, multifocal acquired
demyelinating sensory and motor (MADSAM) CIDP, and pure sensory
subtypes [3]. However, of note, this was not found to be true in all cases
[3]. A teased-fibre preparation of a sural nerve biopsy taken from the
same patients showed sections without myelin due to
macrophages-induced phagocytosis [2]. Moreover, electron microscopy
showed that the macrophages were found within the tubes of basement
membrane, which itself is normally encompassed by myelin [2]. Yet
myelin debris was detected in macrophage cytoplasm [2]. On the other
hand, the cytoplasm of the Schwann cells, found in the outermost layer
of the myelinated fibers, were intact and unaffected by macrophages
[2].
Factors responsible for the phagocytosis of myelin are still unclear
[2]. A recent study examining a sural nerve biopsy through an electron
microscope showed that macrophages tend to target specific sites of the
myelinated fibers [4]. In particular, the region surrounding the nodes of
Ranvier and the internodes in certain patients appear to be major sites of
attack; notably, this is the internal space of the basement membrane,
which encompasses the myelinated fibers [4]. These findings suggest the
presence of local factors that differentiate between the nodal and
internodal region [4]. One possible explanation may be the deposition of
undiscovered antibodies on the peripheral nerves [4]. When the mac
rophages detect these antibodies, they activate, triggering myelin
phagocytosis [4]. In fact, antibodies to a specific peripheral nerve
glycolipid, sialosylneolactotetraosylceramide (LM1), were detected in
cases with macrophages-induced demyelination [5]. Moreover, com
plement (C9) was also found on the myelin. In patients with
Guillain-Barre syndrome (GBS), macrophage-induced demyelination is
morphologically identical to patients with CIDP [6]. In the peripheral
nervous system, foreign epitopes from infectious agents mimic the self
epitope, which leads to autoantibody production [7]. This concept,

molecular mimicry, has been proven in GBS [7]. A similar mechanism
may indeed be responsible for the initial steps of the immunological
process in CIDP [2]. However, studies have not yet shown a direct as
sociation between macrophages and autoantibodies apart from the
study mentioned earlier [5]. Another emerging theory is that of IgG4
autoantibodies [2]. Studies have shown that in patients with CIPD,
specific antibodies act on components of the nodes of Ranvier and
paranodes [4]. Example of these IgG4 autoantibodies include
anti-contactin-1 and anti-neurofascin-155 antibodies, which target the
paranodal junction between axolemma and the myelin terminal loops
[8]. Patients with these antibodies have been found to have distinct
clinical features including tremor and sensory ataxia, as well as being
unresponsive to intravenous immunoglobulin [9]. A sural nerve biopsy
that contained anti-neurofascin-155 and anti-contactin-1 autoantibodies
showed endoneural edema, decreased density of myelinated fibres due
to axonal degradation, and a lack of cellular infiltration due to inflam
mation [10]. These observations are the basis for the alternative path
ogenesis theory of CIPD [2].
CIDP can be divided into a “classical/typical” subtype and into
atypical subtypes, of which there are many, suggesting that it is a
spectrum of disease as classified by the European Federation of Neuro
logical Societies/Peripheral Nerve Society Guidelines on the Manage
ment of CIDP (EFN/PNS) [11,12]. There are five main subtypes of CIDP;
predominantly distal (distal acquired demyelinating symmetric
[DADS]), asymmetrical (multifocal acquired demyelinating sensory and
motor neuropathy [MADSAM]/Lewis-Sumner syndrome), focal, pure
motor or pure sensory [12]. Clinically, it is imperative to distinguish
between classical and atypical phenotypes of the disease as immuno
suppressive drugs that are effective in typical CIDP demonstrate varying
responses in atypical phenotypes [13]. Epidemiologically, only 51% of
patients exhibit the classical phenotype [14]. Patients typically present
with proximal and distal sensorimotor deficits with demyelination that
is defined by the EFNS/PNS Criteria [12]. Pathologically, this definition
includes vertical accumulation of Schwann cell cytoplasmic process,
resulting in onion-bulb formation, segmental demyelination, and
mononuclear
cell
infiltrates
[15].
More
specifically,
macrophage-induced demyelination followed by remyelination is
evident [3]. DADS is an IgM monoclonal protein associated neuropathy
[15]. Clinically, DADS presents with a distal, symmetric
sensory-predominant neuropathy that may cause sensory ataxia. Elec
trophysiology demonstrates abnormally increased distal latencies [16].
Although the accepted pathogenesis of classical CIDP and DADS is
through macrophage-induced demyelination, recent studies also suggest
that patients with autoantibodies against paranodal junction pro
teins—specifically contactin 1- and neurofascin 155-IgG4—may also
present another mechanism by which immune-mediated neuropathies

https://doi.org/10.1016/j.amsu.2021.102545
Received 1 July 2021; Accepted 6 July 2021
Available online 9 July 2021
2049-0801/© 2021 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

Correspondence

Annals of Medicine and Surgery 68 (2021) 102545

are manifested [3,15].
Sensory CIDP commonly presents as a diffuse sensory neuropathy
with chronic progression. When it is restricted to sensory nerve roots,
the phenotype is known as chronic immune sensory polyradiculopathy.
In these cases, electrophysiology studies demonstrate normal motor
nerve conduction velocities. First-line treatment for pure sensory CIDP is
immunomodulatory therapy. Notably, it also responds well to IVIG or
steroids. Therefore, the treatment of pure sensory CIDP is similar to that
of classical CIDP [13]. However, while pure sensory CIDP itself responds
to steroids, one study demonstrated that administration of high dose
steroids in these specific cases may result in unfavorable outcomes. On
the other hand, pure motor CIDP presents with motor deficits with
normal sensory nerve conduction velocities [16,17]. In contrast to pure
sensory CIDP, pure motor CIDP displays an unresponsiveness and even
potential exacerbation of symptoms when treated with steroids [3].
Therefore, IVIG is recommended as first line [13]. Focal CIDP is the least
common form of atypical CIDP, describing motor or sensorimotor neu
ropathy confined to one limb [12,13] Focal CIDP may involve nerve
plexuses or one or more peripheral nerves in an upper or lower limb.
Treatment of the focal phenotype of CIDP is immunomodulatory therapy
that may require maintenance therapy [13].
Demyelinating neuropathies such as GBS and CIDP have been re
ported to be associated with haematological malignancies such as
Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). On the
other hand, GBS and CIDP are rarely associated with solid tumours [18].
Within the literature, GBS and CIDP have been reported as a potential
paraneoplastic neuropathy with carcinoma [19]. For example, Ayyap
pan et al. described the presentation of atypical CIDP, a distal acquired
demyelinating symmetric (DADS), as a paraneoplastic syndrome in a
78-year-old female that was diagnosed with colorectal carcinoma only
one month after being diagnosed with neuropathy. Her neuropathy was
characterised by a 4-month history of distal motor and sensory
involvement, which is typical of DADS. Nerve conduction studies
confirmed a demyelination neuropathy that was consistent with the
diagnosis of DADS neuropathy. Moreover, there was an elevated anti
nuclear antibody (ANA) titre, positive eosinophilia, and positive
myelin-associated glycoprotein (MAG) IgM antibody by immunofluo
rescence essay. No treatment was established for her neuropathy due to
its mild course. After endoscopic diagnosis of her colon adenocarcinoma
and subsequent tumour resection, there was marked improvement of her
clinical neuropathy. Follow up nerve conduction studies no longer
revealed the demyelinating neuropathy and the laboratory studies
returned a negative anti-MAG antibody and positive ANA. This study
drew special attention to the importance of taking into consideration the
paraneoplastic causes in patients diagnosed with subacute neuropathy
[18]. Notably, there is the possibility that colon cancer and neuropathy
may coexist by chance in this patient as colon cancer is not an uncom
mon condition. However, due to the clinical and electrophysiological
remission of neuropathy following tumour removal, the study argued
that this DADS neuropathy was very likely presenting as a paraneo
plastic syndrome related to a tumour-associated immune response [18].
In another study, a similar patient was described with a 2-month
history of acroparesthesias and distal muscle weakness [20]. Nerve
conduction studies were consistent with demyelination. This patient
received monthly IVIG for 42 months, with mild improvement.
Post-therapy, the weakness worsened, and a reduced responsiveness to
immune therapy was observed. To overcome this, IVIG was combined
with steroids and plasmapheresis. However, this was also not effective.
Ten months later, sigmoid colon adenocarcinoma was detected, which
was duly treated with radical hemicolectomy followed by chemo
therapy. Unfortunately, the patient died a year after their cancer diag
nosis. The authors claimed that they were hesitant to consider this
patient’s DADS neuropathy as a paraneoplastic syndrome. There is thus
an unmet need for large, randomised controlled trials regarding the
subject to better elucidate the true aetiology.
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